Indaptus Therapeutics Halts Decoy20 Development, Pivots to Strategic Review After $12 Million Financing
核心洞察
Indaptus Therapeutics discontinued enrollment in its Decoy20 combination study and now has no active clinical development programs, pausing further development of its lead immunotherapy candidate.
The company completed a $12.0 million private placement in June 2026, issuing 20 million shares at $0.60 per share, strengthening its liquidity position to approximately $11.6 million in cash and investments.
Research and development expenses fell 83% to $0.4 million in Q2 2026, while net loss narrowed to $1.8 million from $5.2 million a year earlier.
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company dedicated to immunotherapy research, announced on August 13, 2026 that it has discontinued further enrollment in its Decoy20 combination study and currently has no active clinical development programs. The company reported financial results for the second quarter and six months ended June 30, 2026, alongside a corporate update detailing its strategic pivot away from its lead immunotherapy candidate.
Junyi Dai, Indaptus Therapeutics' Chief Executive Officer and Chairman of the Board, stated, "During the second quarter, we strengthened the Company's balance sheet through a $12.0 million private placement and continued our review of the Decoy platform, our research activities and broader strategic alternatives. We are evaluating how our existing therapeutic assets, complementary research capabilities and potential strategic investments or business combinations may support the Company's long-term objectives."
Strategic Review and Decoy20 Status
The company has discontinued further enrollment in its combination study and reports no participants remaining in any ongoing Decoy20 clinical study. Indaptus has reduced activities related to further development of Decoy20 while it evaluates strategic alternatives for the Decoy20 program and broader operations. These alternatives include research collaborations, investments in or acquisitions of operating businesses, and other potential growth opportunities.
Decoy20 is a novel anti-cancer and anti-viral immunotherapy that had been under evaluation in Phase 1 clinical trials in advanced solid tumors (搜索) after prior therapies had failed. The company's patented Decoy technology uses attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate multiple components of innate and adaptive immunity while reducing systemic toxicity.
New Research Direction in Neurological Disorders
During the second quarter, Indaptus began a research collaboration in neurological disorders and sleep as an extension of its immunotherapy research. Mr. Dai commented, "We also began a research collaboration in neurological disorders and sleep as an extension of our immunotherapy research. As we allocate capital and evaluate potential opportunities, we intend to proceed in a disciplined manner based on scientific validation, strategic fit, regulatory considerations and available resources."
The company indicated it seeks to better understand the relationship among sleep, physical recovery, neurological function and immune status, which could potentially support future immunotherapy evaluation, patient recovery monitoring and biomarker research.
Financial Results
Research and development expenses decreased 83% to approximately $0.4 million for the second quarter of 2026, compared with $2.2 million for the same period in 2025. For the first six months of 2026, R&D expenses also decreased 83% to approximately $0.9 million, compared with $5.0 million in 2025. The decreases were primarily due to lower clinical costs for the Decoy20 Phase 1 study and lower payroll and related expenses following reductions in headcount and base salaries.
General and administrative expenses decreased 37% to approximately $1.4 million for the second quarter of 2026, compared with $2.3 million for the same period in 2025. For the first six months of 2026, G&A expenses decreased 23% to approximately $3.1 million, compared with $4.1 million in 2025.
Net loss decreased to approximately $1.8 million for the second quarter of 2026, compared with $5.2 million for the same period in 2025. For the first six months of 2026, net loss decreased to approximately $4.3 million, compared with $9.8 million in 2025. Basic and diluted net loss per share was approximately $0.02 and $0.07 for the respective periods, compared with $9.09 and $18.09 in 2025.
Liquidity Position
On June 17, 2026, the company issued and sold 20,000,000 shares of common stock at $0.60 per share for aggregate gross proceeds of approximately $12.0 million before offering expenses. The transaction closed on the same day.
As of June 30, 2026, the company had approximately $11.6 million in cash, cash equivalents and short-term investments, consisting of $7.6 million in cash and cash equivalents and $4.0 million in short-term investments. Management noted that the company's liquidity position improved primarily due to the $12.0 million financing completed in June 2026, and that it has been strengthened compared to the first quarter end. The company may seek additional public or private equity or debt financing to support its operations and strategic objectives.